Hospital
Athens Hospital, LLC
Athens Hospital, LLC was paid $8.32M by Medicaid between Sep 2020 and Dec 2024, across 90 billing codes. Its largest line is 99284, emergency room visit (serious) — 42% of everything it billed.
33Billing provider infoATHENS HOSPITAL, LLC
ATHENS, TX 75751
ATHENS, TX 75751
33aNPI1417465824assigned 01/19/2018
33bProvider typeGeneral Acute Care Hospital
28Total paid$8.32M
24GClaims123,639
24DCodes billed90
24AFirst – last monthSep 2020 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Texas
Rank by total paid#20 of 109
Median peer was paid$1.15M
This provider vs. median7.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official PETROVICH, STEPHEN controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 1,313 | $60K | |
| 2021 | 22,627 | $1.03M | |
| 2022 | 46,601 | $3.02M | |
| 2023 | 39,991 | $3.22M | |
| 2024incomplete | 13,107 | $988K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 42% | 10,724 | 9,914 | $3.46M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 20% | 4,721 | 3,983 | $1.66M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 20,561 | 19,700 | $995K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 6.2% | 3,224 | 3,095 | $511K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.2% | 3,203 | 2,331 | $184K |
| 71045 | Radiologic examination, chest; single view | 1.7% | 4,411 | 3,807 | $144K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.7% | 484 | 466 | $142K |
| 80053 | Comprehensive metabolic panel | 1.6% | 10,381 | 8,741 | $129K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.3% | 345 | 307 | $111K |
| 87430 | 1.2% | 3,069 | 2,969 | $104K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 10,323 | 8,532 | $95K |
| 87428 | 1.1% | 1,161 | 1,122 | $91K |
78 more codes
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,320 | $80K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 878 | $68K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,006 | $56K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 425 | $54K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 191 | $37K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 681 | $32K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 277 | $29K |
| 81001 | <1% | 7,246 | $29K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 31 | $23K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,059 | $20K |
| 84484 | <1% | 1,971 | $19K | |
| 83880 | <1% | 679 | $17K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 468 | $15K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 293 | $14K |
| 80061 | Lipid panel | <1% | 893 | $13K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,253 | $13K |
| 87081 | <1% | 650 | $13K | |
| 99001 | <1% | 323 | $12K | |
| 87420 | <1% | 362 | $11K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 223 | $11K |
| 84703 | <1% | 1,090 | $11K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 262 | $10K |
| CP008 | <1% | 217 | $10K | |
| G0378 | Hospital observation service, per hour | <1% | 14 | $9K |
| 83690 | <1% | 1,177 | $8K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 550 | $7K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 26 | $6K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 50 | $6K |
| 59050 | <1% | 45 | $6K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 965 | $5K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 609 | $4K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 100 | $4K |
| 87040 | <1% | 413 | $4K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 55 | $4K |
| 83735 | <1% | 839 | $4K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 778 | $3K |
| 83605 | <1% | 295 | $3K | |
| 85610 | <1% | 977 | $3K | |
| 59025 | Fetal non-stress test | <1% | 50 | $2K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 154 | $2K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 12 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 529 | $2K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 912 | $1K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 315 | $1K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 686 | $1K |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 249 | $947.67 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 25 | $864.66 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,339 | $838.04 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 200 | $764.06 |
| 36415 | Collection of venous blood by venipuncture | <1% | 12,391 | $712.56 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 73 | $684.54 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 305 | $627.67 |
| 82550 | <1% | 96 | $557.86 | |
| 87077 | <1% | 47 | $548.34 | |
| 87186 | <1% | 45 | $398.75 | |
| 85027 | <1% | 174 | $375.42 | |
| 84439 | <1% | 51 | $360.05 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 19 | $307.98 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 273 | $247.88 |
| 85730 | <1% | 176 | $228.50 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 72 | $212.64 |
| 85007 | <1% | 164 | $192.23 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 806 | $187.66 |
| 84030 | <1% | 13 | $140.08 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 33 | $128.19 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 170 | $85.90 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 14 | $85.50 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 13 | $61.10 |
| 85018 | <1% | 13 | $42.25 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 13 | $37.67 |
| 82150 | <1% | 14 | $26.93 | |
| 82962 | <1% | 682 | $6.56 | |
| J2704 | Injection, propofol, 10 mg | <1% | 91 | $0.44 |
| A9270 | Non-covered item or service | 0% | 1,447 | $0.00 |
| 96376 | 0% | 14 | $0.00 | |
| 36416 | 0% | 12 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 635 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPETROVICH, STEPHEN (EVP AND SECRETARY)
| Provider | Location | Paid |
|---|---|---|
| Lovelace Health System, LLC | Albuquerque, NM | $57.71M |
| Lovelace Health System LLC | Albuquerque, NM | $45.27M |
| Southwest Medical Associates, LLC | Albuquerque, NM | $41.40M |
| Lovelace Health System, LLC | Albuquerque, NM | $31.24M |
| Lovelace Health System LLC | Roswell, NM | $20.13M |
| Jacksonville Hospital LLC | Jacksonville, TX | $9.41M |
| Henderson Hospital, LLC | Henderson, TX | $8.52M |
| Etmc Physician Group INC. | Tyler, TX | $8.03M |
| Tyler Regional Hospital LLC | Tyler, TX | $7.94M |
| Lovelace UNM Rehabilitation Hospital LLC | Albuquerque, NM | $6.30M |
| Pocatello Hospital LLC | Pocatello, ID | $6.11M |
| Jacksonville Hospital LLC | Jacksonville, TX | $5.93M |
| Ahs Pryor Hospital, LLC | Pryor, OK | $5.61M |
| Bsa Hospital LLC | Amarillo, TX | $4.96M |
| Pittsburg Hospital LLC | Pittsburg, TX | $4.83M |
| Ahs Claremore Regional Hospital, LLC. | Claremore, OK | $4.81M |
| Ahs Henryetta Hospital LLC | Henryetta, OK | $4.27M |
| Pittsburg Hospital LLC | Pittsburg, TX | $3.98M |
| Topeka Hospital, LLC | Topeka, KS | $3.94M |
| Ahs Pryor Hospital, LLC | Pryor, OK | $3.76M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.